{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:55:57Z","timestamp":1757699757910,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FCT","award":["SFRH\/BD\/78256\/2011"],"award-info":[{"award-number":["SFRH\/BD\/78256\/2011"]}]},{"name":"BIAL-Portela & Ca S.A."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejps.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T07:37:12Z","timestamp":1518075432000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In vitro assessment of the interactions of dopamine \u03b2-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein"],"prefix":"10.1016","volume":"117","author":[{"given":"Joana","family":"Bicker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.02.006_bb0005","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast Cancer Resistance Protein and P-glycoprotein in brain cancer: two gatekeepers team up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2018.02.006_bb0010","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2013.10.012","article-title":"Etamicastat, a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension","volume":"35","author":"Almeida","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2018.02.006_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/aapsj080101","article-title":"Current industrial practices of assessing permeability and P-glycoprotein interaction","volume":"8","author":"Balimane","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2018.02.006_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.362","article-title":"Pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood\u2013brain barrier","volume":"100","author":"Bauer","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.02.006_bb0025","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm051051f","article-title":"Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase","volume":"49","author":"Beliaev","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.02.006_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/157340809787314265","article-title":"Dopamine beta-monooxygenase: mechanism, substrates and inhibitors","volume":"5","author":"Beliaev","year":"2009","journal-title":"Curr. Enzym. Inhib."},{"key":"10.1016\/j.ejps.2018.02.006_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.01.074","article-title":"A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates","volume":"501","author":"Bicker","year":"2016","journal-title":"Int. J. Pharm."},{"year":"2007","series-title":"Determination of Drug Absorption Parameters in Caco-2 Cell Monolayers With a Mathematical Model Encompassing Passive Diffusion, Carrier-mediated Efflux, Non-specific Binding and Phase II Metabolism. Univ. Basel","author":"Blaser","key":"10.1016\/j.ejps.2018.02.006_bb0040"},{"key":"10.1016\/j.ejps.2018.02.006_bb0045","article-title":"BIA 5-1058 is a new noncompetitive dopamine-\u03b2-hydroxylase inhibitor","volume":"10","author":"Bonif\u00e1cio","year":"2012","journal-title":"Br. Pharmacol. Soc."},{"key":"10.1016\/j.ejps.2018.02.006_bb0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2015.01.034","article-title":"Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-\u03b2-hydroxylase: comparison with nepicastat","volume":"751","author":"Bonif\u00e1cio","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.02.006_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2018.02.006_bb0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery","volume":"56","author":"Di","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.02.006_bb0065","series-title":"Guideline on Bioanalytical Method Validation: EMEA\/CHMP\/EWP\/192217\/2009 Rev.1 Corr.*","first-page":"1","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.ejps.2018.02.006_bb0070","series-title":"Guideline on the Investigation of Drug Interactions. CPMP\/EWP\/560\/95\/Rev. 1 Corr.*","first-page":"1","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.ejps.2018.02.006_bb0075","series-title":"Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations","first-page":"1","author":"Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.ejps.2018.02.006_bb0080","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1002\/jps.22632","article-title":"Interactions between organic anions on multiple transporters in Caco-2 cells","volume":"100","author":"Grandvuinet","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.02.006_bb0085","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejpb.2012.07.020","article-title":"Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models","volume":"82","author":"Hellinger","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.02.006_bb0090","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejps.2018.02.006_bb0095","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1097\/01.hjh.0000420843.24708.5e","article-title":"Antihypertensive effect of BIA 5-1058 a new selective peripheral dopamine beta-hydroxylase inhibitor","volume":"30","author":"Igreja","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2018.02.006_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.31.1_supplement.1070.7","article-title":"Effect of chronic treatment with zamicastat on right ventricle pressure overload in the rat monocrotaline lung injury model of pulmonary hypertension","volume":"31","author":"Igreja","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2018.02.006_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.02.006_bb0110","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/jpet.109.162321","article-title":"Kinetic analysis of the cooperation of P-glycoprotein (P-gp\/Abcb1) and Breast Cancer Resistance Protein (Bcrp\/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone","volume":"333","author":"Kodaira","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2018.02.006_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2133\/dmpk.24.37","article-title":"In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney","volume":"24","author":"Kusuhara","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.02.006_bb0120","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3109\/00498254.2015.1018985","article-title":"Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat","volume":"45","author":"Loureiro","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2018.02.006_bb0125","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11095-005-9304-3","article-title":"Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells","volume":"23","author":"Neuhoff","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.02.006_bb0130","series-title":"Drug Delivery to the Brain: Physiological Concepts, Methodologies and Approaches","first-page":"339","article-title":"Chapter 12. Integrated approach to optimizing CNS penetration in drug discovery: from the old to the new paradigm and assessment of drug\u2013transporter interactions","author":"Reichel","year":"2014"},{"key":"10.1016\/j.ejps.2018.02.006_bb0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/0091270010390805","article-title":"Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine beta-hydroxylase inhibitor, in healthy subjects","volume":"52","author":"Rocha","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.02.006_bb0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/dmd.105.007377","article-title":"Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values","volume":"34","author":"Weiss","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.02.006_bb0145","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.1.4.595","article-title":"Breast Cancer Resistance Protein in pharmacokinetics and drug-drug interactions","volume":"1","author":"Xia","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871830068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871830068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:56:10Z","timestamp":1719798970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809871830068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":29,"alternative-id":["S092809871830068X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.02.006","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro assessment of the interactions of dopamine \u03b2-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}